Research and Development Collaboration and License Agreements (Tables)

9 Months Ended

Sep. 30, 2012

Revenue From Significant Collaboration Partners As Percentage of Contract Revenue

The following table presents a summary of revenue from significant collaboration partners as a percentage of the Company’s contract revenue:

	Year Ended December 31,									Nine Months Ended September 30,
	2009			2010			2011			2011			2012
										(unaudited)
Sanofi		—	%		100	%		100	%		100	%		100	%
Novartis		49	%		—	%		—	%		—	%		—	%
Other		51	%		—	%		—	%		—	%		—	%

Revenue Recognized Under Sanofi Agreement

Revenue recognized under the Sanofi agreement was as follows:

	Years Ended December 31,				Nine Months Ended September 30,
(in thousands)	2010		2011		2011		2012
					(unaudited)
Contract revenue:
Amortization of upfront fees	$	15,393	$	18,977	$	13,285	$	5,630
Reimbursement for development-related activities		2,319		1,278		1,101		450
Total contract revenue	$	17,712	$	20,255	$	14,386	$	6,080